West Family Investments Inc. Invests $603,000 in Bristol Myers Squibb Company $BMY

West Family Investments Inc. bought a new position in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, Holdings Channel.com reports. The fund bought 10,464 shares of the biopharmaceutical company’s stock, valued at approximately $603,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. BlackRock Inc. increased its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the period. Geode Capital Management LLC raised its holdings in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Finally, Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $1,947,272,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $67.59 on Thursday. The stock has a market capitalization of $138.06 billion, a P/E ratio of 14.89, a P/E/G ratio of 0.17 and a beta of 0.22. The business has a 50-day moving average of $60.18 and a two-hundred day moving average of $59.24. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the firm posted $1.46 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Raymond James Financial started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Citigroup reiterated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a research report on Wednesday, August 5th. Finally, Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.